MSB 5.50% $1.38 mesoblast limited

FDA ODAC Meeting Material discussion analysis, page-165

  1. 11,474 Posts.
    lightbulb Created with Sketch. 511
    It appears to me this is the FDA covering there backside so to speak and ensuring expert panel discuss older trial results.

    Everything must be discussed.

    FDA conclusion on safety and efficiency is the statement of what they are thinking pre meeting. Imo.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.